Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the approval of the US FDA for the company's injectable use of cetrorelix acetate
Announcement of Resolutions of the 39th Meeting of the Eighth Board of Directors of Health Yuan Pharmaceutical Group Co., Ltd.
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the Company's provision of an entrustment loan to the holding subsidiary Jiaozuo Jianfeng
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on cancellation of some stock options of the 2022 Stock Options Incentive Plan
Legal Opinion of Beijing Zhonglun Law Firm on the Cancellation of Part of the 2022 Stock Options Incentive Plan by Health Yuan Pharmaceutical Group Co., Ltd. that have not yet exercised rights
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the use of letters of credit to pay for fund-raising project funds and replace them in equal amounts with raised funds
Verification opinion of Minsheng Securities Co., Ltd. on the use of letters of credit by Jiankyuan Pharmaceutical Group Co., Ltd. to pay funds for fund-raising projects and replace them in equal amounts with the raised funds
Announcement of Resolutions of the 31st Meeting of the Eighth Board of Supervisors of Health Yuan Pharmaceutical Group Co., Ltd.
Review opinions of Health Yuan Pharmaceutical Group Co., Ltd. on proposals related to the 31st meeting of the 8th board of supervisors of the company
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the appointment of the company's senior management
Health Yuan Pharmaceutical Group Co., Ltd. Report for the first quarter of 2024
Health Yuan Pharmaceutical Group Co., Ltd. 2024 First Quarter Report (English version)
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on holding a performance briefing for the first quarter of 2023 and 2024
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Health Yuan Pharmaceutical Group Co., Ltd.
Legal Opinion of Beijing Deheng (Shenzhen) Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Health Yuan Pharmaceutical Group Co., Ltd.
An indicative announcement of Health Yuan Pharmaceutical Group Co., Ltd. on convening the 2024 Second Extraordinary General Meeting of Shareholders
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on reaching the main end of the TG-1000 capsule phase III clinical trial
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the independent exercise results and share changes of the company's 2022 stock options incentive plan for the first quarter of 2024
Announcement of Health Yuan Pharmaceutical Group Co., Ltd. on the progress of providing guarantees
An indicative announcement by Health Yuan Pharmaceutical Group Co., Ltd. on the stock option incentive plan to limit the exercise period
No Data